ArticleHeliyon2024

Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis.

Fei Tong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.